ArticleCurrent hepatology reports2019
Harms of hepatocellular carcinoma surveillance.
Article in Current hepatology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Hepatocellular carcinoma tumour volume doubling time: a systematic review and meta-analysis.Gut · 2021Pooled it
- The Malaysian Society of Gastroenterology and Hepatology Consensus Statements on Prevention and Early Detection of Hepatocellular Carcinoma in Malaysia.Journal of gastroenterology and hepatology · 2026Review
- Proposal for Modified Alpha Fetoprotein Use in Hepatocellular Carcinoma Surveillance: Analysis of the 2018-2020 National Cancer Screening Program.Journal of Korean medical science · 2026Article
- Psychosocial impact of false-positive surveillance for hepatocellular carcinoma: a qualitative study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- HES V2.0 validation and performance compared to GALAD and ASAP in the HEDS cohort.Journal of hepatology · 2026Article
- Putative Imprinting Control Regions with Aberrant Blood-Based DNA Methylation are Associated with Hepatocellular Carcinoma Risk.Journal of hepatocellular carcinoma · 2026Article
- Abbreviated MRI-Based Surveillance Strategies for Early Hepatocellular Carcinoma Detection.Journal of the Korean Society of Radiology · 2025Review
- Surveillance for Hepatocellular Carcinoma in Patients with Successfully Treated Viral Disease of the Liver: A Systematic Review.Liver cancer · 2024Review
- Hepatocellular Carcinoma from a Hepatologist's Perspective.Seminars in interventional radiology · 2023Review
- Hepatocellular Carcinoma Risk Scores Predict Patients Under Surveillance at Low Risk of Benefit and High Risk of Harm.Digestive diseases and sciences · 2023Article
- Current Landscape and Future Perspectives of Abbreviated MRI for Hepatocellular Carcinoma Surveillance.Korean journal of radiology · 2022Review
- Overdiagnosis of hepatocellular carcinoma: Prevented by guidelines?Hepatology (Baltimore, Md.) · 2022Review
- Impact of ultrasonographic blind spots for early-stage hepatocellular carcinoma during surveillance.PloS one · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purpose of reviewHepatocellular carcinoma (HCC) surveillance in patients with cirrhosis is associated with decreased mortality by enabling early tumor detection. However, the benefits of any cancer screening program must be considered in light of potential physical, financial, and psychological harms, as well as the risk of overdiagnosis. Herein, we summarize the potential harms of HCC surveillance. RECENT
findingsTo date, two retrospective studies have addressed physical harms of HCC surveillance. Based on these data, 15% to 28% of patients undergoing HCC surveillance experience physical harm including additional cross-sectional imaging or liver biopsy. Although psychological and financial harms have been reported for other cancers, there are currently limited data specific to HCC. An ongoing multi-center prospective study assessing all four types of harms should provide data in near future. SUMMARY: HCC screening may prevent death by diagnosing tumors at an early stage, but limited sensitivity and specificity of screening tests can result in unintended harms. There is a need for further quality data evaluating both the benefits and harms of HCC surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.